» Authors » Brian P Hobbs

Brian P Hobbs

Explore the profile of Brian P Hobbs including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 102
Citations 2173
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Cottrell T, Lotze M, Ali A, Bifulco C, Capitini C, Chow L, et al.
J Immunother Cancer . 2025 Mar; 13(3). PMID: 40054999
Immunotherapy of cancer is now an essential pillar of treatment for patients with many individual tumor types. Novel immune targets and technical advances are driving a rapid exploration of new...
2.
Chen Y, Chu Y, van Rossum P, Grassberger C, Lin S, Mohan R, et al.
Adv Radiat Oncol . 2024 Sep; 9(10):101579. PMID: 39258141
Purpose: Radiation-induced lymphopenia (RIL) is common during chemoradiation therapy. Severe lymphopenia is associated with reduced survival. Proton beam therapy (PBT), with its substantially more compact dose distributions, spares circulating lymphocytes...
3.
Hu Z, Mohan R, Chu Y, Wang X, van Rossum P, Chen Y, et al.
Int J Part Ther . 2024 Sep; 13:100624. PMID: 39228692
Purpose: Radiation-induced lymphopenia is a common immune toxicity that adversely impacts treatment outcomes. We report here our approach to translate a deep-learning (DL) model developed to predict severe lymphopenia risk...
4.
Ng C, Chandler A, Chen Y, Wei W, Tannir N, Hobbs B
Res Diagn Interv Imaging . 2024 Jul; 6:100028. PMID: 39077545
Objective: CT perfusion (CTp) values are affected by CT scan acquisition duration (t); their reproducibility is adversely affected by uncertainty in their measurement. The objectives were to assess the effects...
5.
Yu D, Kane M, Koay E, Wistuba I, Hobbs B
Sci Rep . 2024 Jul; 14(1):15004. PMID: 38951567
The tumor microenvironment (TME) plays a fundamental role in tumorigenesis, tumor progression, and anti-cancer immunity potential of emerging cancer therapeutics. Understanding inter-patient TME heterogeneity, however, remains a challenge to efficient...
6.
Chu Y, Zhu C, Hobbs B, Chen Y, van Rossum P, Grassberger C, et al.
Int J Radiat Oncol Biol Phys . 2024 May; 120(4):1172-1180. PMID: 38797500
Purpose: Radiation-induced lymphopenia (RIL) is common among patients undergoing radiation therapy (RT)' Severe RIL has been linked to adverse outcomes. The severity and risk of RIL can be predicted from...
7.
Damen P, van Rossum P, Chen Y, Abana C, Liao Z, Hobbs B, et al.
Int J Part Ther . 2024 May; 11:100012. PMID: 38757082
Purpose: Evidence suggests that proton-beam therapy (PBT) results in less toxicity and postoperative complications compared to photon-based radiotherapy in patients who receive chemoradiotherapy followed by esophagectomy for cancer. Ninety-day mortality...
8.
Wang X, van Rossum P, Chu Y, Hobbs B, Grassberger C, Hong T, et al.
Int J Radiat Oncol Biol Phys . 2023 Aug; 118(2):368-377. PMID: 37652304
Purpose: Lymphocytes play an important role in antitumor immunity; however, they are also especially vulnerable to depletion during chemoradiation therapy (CRT). The purpose of this study was to compare the...
9.
Abe J, Imanishi M, Li S, Zhang A, Ko K, Samanthapudi V, et al.
Circ Res . 2023 Jun; 133(1):25-44. PMID: 37264926
Background: ERK5 (extracellular signal-regulated kinase 5) is a dual kinase transcription factor containing an N-terminal kinase domain and a C-terminal transcriptional activation domain. Many ERK5 kinase inhibitors have been developed...
10.
Zhou J, Jiang X, Xia H, Hobbs B, Wei P
Front Oncol . 2023 Feb; 12:999324. PMID: 36733365
Clinical cancer trials are designed to collect radiographic measurements of each patient's baseline and residual tumor burden at regular intervals over the course of study. For solid tumors, the extent...